Astria Therapeutics (ATXS) Stock Analysis

What Astria Therapeutics does

Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.

Key metrics

ETFs linked to ATXS

Broad-market and Healthcare sector ETFs an investor holding Astria Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ATXS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Astria Therapeutics?

Astria Therapeutics trades under the ticker ATXS on NASDAQ.

Which exchange is ATXS listed on?

ATXS is listed on NASDAQ.

What sector does Astria Therapeutics operate in?

Astria Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ATXS in a portfolio?

PortView shows ATXS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.